Philip M. Arlen, M.D.


  • Target is broadly expressed in multiple solid tumors.
  • Exhibits both ADCC and CDC killing.
  • Promising pre-clinical results with complete regression of tumor in animal models.
  • GMP manufacturing completed.
  • Pre-clinical testing showed that NEO-201 was well tolerated in cynomolgus monkeys even at high doses.
  • Preclinical changes in hematologic laboratory values represents an on-target side effect that
    appears to be reversible, and supports infusion schedule of every two weeks.
  • FDA approved IND July 2018
  • 1st in Human Study initiated at NCI Q1 2019

Presentation – Novel Targets of Neoantigens in Monoclonal Antibodies